EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial

Austin McCullough, Charles D Chen, Brian A Gordon, Nelly Joseph-Mathurin, Clifford R Jack, Robert Koeppe, Russ Hornbeck, Deborah Koudelis, Nicole S McKay, Diana A Hobbs, Shaney Flores, Sarah J Keefe und 40 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70347 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Austin McCullough und 51 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine in Saint Louis, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, F. Hoffman-LaRoche Ltd, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBrainAntibodies, Monoclonal, HumanizedHumansPositron-Emission TomographyMaleFemaleMagnetic Resonance ImagingNeuroimagingMiddle AgedBiomarkersThiazolesFluorodeoxyglucose F18Aniline CompoundsAgedAmyloid beta-Peptides

Stichwörter der Autor:innen

DIAN‐TUFDG‐PETMRI measuresPETamyloid targeted monoclonal antibodyautosomal dominant Alzheimer's disease (ADAD)dominantly inherited Alzheimer's disease (DIAD)gantenerumabimaging outcomesregional PiB‐PET uptakeregional variability

Substanzen

Antibodies, Monoclonal, HumanizedgantenerumabBiomarkersThiazolesFluorodeoxyglucose F18Aniline Compounds2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-Peptides

Autor:innen und Institutionen

  • Washington University School of Medicine in Saint Louis, St. Louis, Missouri, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • University of Michigan, Ann Arbor, Michigan, USA.
  • Rush University Medical Center, Chicago, Illinois, USA.
  • Institute for Neurological Research FLENI, Buenos Aires, Argentina.
  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Förderung

  • NIA NIH HHS
  • F. Hoffman-LaRoche Ltd
  • NIH HHS
  • F. Hoffman-LaRoche Ltd.
  • BrightFocus Foundation
  • N.J.M.
  • GHR Foundation
  • Alzheimer's Association

Zitieren

APA

McCullough, A., Chen, C. D., Gordon, B. A., Joseph-Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R., Koudelis, D., McKay, N. S., Hobbs, D. A., Flores, S., Keefe, S. J., Aggarwal, N. T., Allegri, R. F., Berman, S. B., Bird, T., Black, S. E., Brooks, W. S., Chhatwal, J. P., …, & DIAN‐TU Study Team (2025). Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70347

Vancouver

McCullough A, Chen CD, Gordon BA, Joseph-Mathurin N, Jack CR, Koeppe R, et al. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70347

BibTeX
@article{McCullough2025,
  author = {McCullough, Austin and Chen, Charles D and Gordon, Brian A and Joseph-Mathurin, Nelly and Jack, Clifford R and Koeppe, Robert and Hornbeck, Russ and Koudelis, Deborah and McKay, Nicole S and Hobbs, Diana A and Flores, Shaney and Keefe, Sarah J and Aggarwal, Neelum T and Allegri, Ricardo F and Berman, Sarah B and Bird, Thomas and Black, Sandra E and Brooks, William S and Chhatwal, Jasmeer P and Day, Gregory S and Farlow, Martin R and Fox, Nick C and Gauthier, Serge and Honig, Lawrence S and Hsiung, Ging-Yuek and Jucker, Mathias and Levin, Johannes and Masellis, Mario and Masters, Colin and Mendez, Patricio Chrem and Ringman, John M and Snider, B Joy and Salloway, Stephen and Schofield, Peter R and Shimada, Hiroyuki and Suzuki, Kazushi and van Dyck, Christopher H and Klein, Gregory and Clifford, David B and Cruchaga, Carlos and Hassenstab, Jason and Li, Yan and McDade, Eric and Mills, Susan and Morris, John C and Perrin, Richard J and Supnet-Bell, Charlene and Wang, Guoqiao and Xiong, Chengjie and Bateman, Randall J and Benzinger, Tammie L S and DIAN‐TU Study Team, DIAN‐TU Study Team},
  title = {Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70347}
}
Kostenlos starten →